Otsuka Holdings came into this Q3 2026 print with a stock that has drifted in recent days, down about 3.5% over the past week but still ahead over three months. The fresh headline is simple. Revenue reached ¥710,049m and basic earnings per share landed at ¥202.96, while the trailing twelve month P/E sits around 16.2x, roughly in line with peers but above the broader pharmaceuticals group. That combination creates a clear expectation gap if you focus on one thing. Profitability is under pressure and margin quality, not just the sales line, is setting the tone for this earnings season.
Like the earnings power at Otsuka Holdings but uneasy about margin pressure at a mid teens P/E? Consider a shortlist of companies that pair resilient profitability with cleaner balance sheets in our list of solid balance sheet and fundamentals stocks (21 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): ¥710,049 million vs. ¥637,977 million (up about 11%)
- Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): ¥106,493 million vs. ¥124,129 million (down about 14%)
- Basic EPS (Q3 2026 vs. Q3 2025): ¥202.96 vs. ¥235.05 (declined about 14%)
- R&D Pipeline Depth (Q3 2026 vs. Q3 2025): Phase I products 4 vs. 5, Phase II products 1 vs. 2, Phase III products 1 vs. 3, products in pre registration 0 vs. 4
Earnings forecasts lag the market even as the DCF upside looks large. Ask Charlie what Otsuka’s valuation gap really reflects.
Otsuka’s Bull Case Meets Mixed Margin Reality
The bullish pitch rests on newer drugs and consumer brands carrying Otsuka Holdings through patent and cost pressure.
"The main factor that would need to work out is that recently launched and late stage therapies in autoimmune and CNS, together with the expanding nutraceutical and consumer health portfolio, collectively offset loss of exclusivity headwinds and higher R&D and SG&A spending."
Q3 shows this hurdle is still high. Revenue rose about 11%, yet net income and EPS each fell about 14%. That gap signals higher spend and loss of exclusivity are affecting results faster than new autoimmune, CNS and nutraceutical contributions are flowing through the income statement.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.
Otsuka Holdings: Revenue Strength, Margin Fears Confirmed
Bearish analysts argue that Otsuka Holdings risks letting strong sales momentum leak away into higher fixed costs and launch spending.
"bearish analysts expect Otsuka Holdings to face a squeeze between sustained high R&D spending and rising capital needs for late-stage assets, which could limit how much of the recent revenue and profit strength actually reaches long-term earnings per share."
This quarter edges in that direction. Revenue climbed while net income and EPS each fell about 14%. That pattern points to exactly the squeeze bears describe, with higher R&D and commercialization spending showing up ahead of matching pipeline revenue and leaving margins weaker despite a solid top line.
Hunt For Earnings Disconnects
Otsuka Holdings just showed how solid revenue can coexist with compressed profitability and a drifting share price. The real opportunity could sit in companies where fundamentals improve before valuations fully catch up.
- Company 1 - 21% below our estimate - supplies high specification connectors increasingly designed into smartphones, vehicles and factory equipment as data speeds and reliability demands accelerate.
- Company 2 - 44% below our estimate - extends a regional banking platform that folds in fee businesses from leasing, credit cards and real estate alongside traditional lending and deposits.
- Company 3 - 33% below our estimate - produces advanced photomasks that chip manufacturers adopt when moving production toward finer geometries and more complex packaging designs.
Those are three of them. See all 15 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com